Pharma BD Deal Intelligence
Merck & Co. has expanded its antibody-drug conjugate partnership with China's Kelun-Biotech, agreeing to pay $35 million upfront for rights outside of Greater…
Merck is back at the negotiating table with Kelun-Biotech, paying the Chinese biotech $35 million upfront for a second antibody-drug conjugate asset in solid…
Kelun-Biotech received an upfront payment of $175 million and is eligible to receive milestone payments totaling up to $9.3 billion.
Source summaries from our enrichment pipeline; follow links for originals.
All 19 sources with sentiment breakdown →
Merck licensed a second ADC candidate from Kelun-Biotech for solid tumor treatment, the second of three ADC deals in 2022.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Kelun-Biotech Biopharmaceuticals Co. Ltd. (this deal) | 2022 | $936M | 60 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2022 deals · Merck & Co. Inc. deals · Oncology deals